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Summary 
It is generally accepted that carcinogenic substances in the form of tobacco, alcohol or 
oncogenic viruses, etc cause genetic changes resulting in conversion of normal oral 
epithelium to a potentially malignant (dysplastic) lesion, and subsequently into the invasive 
oral squamous cell carcinoma (OSCC). However, the precise molecular mechanism 
underlying OSCC carcinogenesis remains unclear. Several members of the multifunctional 
Ca2+ binding S100 proteins have been described in connection with a range of human cancers, 
including OSCCs. Studies from our group, using high throughput genomic and proteomic 
methods, have previously identified differential expression of members of the S100 proteins 
in OSCCs from different populations. S100A14 is a recently identified member of the S100 
protein family. Although differential expression of S100A14 has been described in different 
human cancers, its biological roles in carcinogenesis have not been well characterized. This 
study aimed (i) to examine the mRNA expression profile of 16 of the S100 gene family 
members in OSCCs and (ii) to characterize the possible role(s) of S100A14 in proliferation 
and invasion of OSCC derived cells. 
 We identified significant down-regulation of S100A4, S100A6, S100A8 and S100A14 
mRNAs in OSCCs compared to their pair-wised controls. Down-regulation of S100A14 was 
further validated at the protein level in OSCC archival tissues using immunohistochemistry, 
and in an in vitro oral cancer progression model both at the mRNA and protein levels. To 
investigate the functional roles of S100A14, we employed retroviral vector mediated over-
expression and siRNA mediated knock-down of the endogenous S100A14 in two OSCC 
derived cell-lines (CaLH3 and H357). S100A14 over-expression resulted in a significant 
reduction in CaLH3 cell proliferation due to G1-phase cell cycle arrest, but not apoptosis. 
This G1- arrest was found to be associated with nuclear accumulation of the tumor suppressor 
protein p53 and p53-dependent up-regulation of p21. These findings suggest a functional link 
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between S100A14 and cell-cycle regulators p53 and p21 in the regulation of cell cycle in 
OSCC derived cells and support the idea that S100A14 might function as a tumor suppressor 
protein working in the p53 pathway. 
 Characterization of the role of S100A14 in tumor invasion showed that over-
expression of S100A14 resulted in a significant decrease in the invasive potential of the 
OSCC derived CaLH3 and H357 cell-lines, whereas siRNA mediated knock-down resulted in 
a significant increase in the invasive potential of the CaLH3 cell-line in vitro. PCR array and 
validation using qRT-PCR and gelatin zymography revealed that S100A14 over-expression 
was associated with down-regulation of MMP1 and MMP9 mRNAs in both CaLH3 and H357 
cell-lines and suppression of MMP9 activity in the CaLH3 cell-line. Additionally, an inverse 
correlation between mRNA expression levels of MMP1 and MMP9 with S100A14 was found 
in OSCC tissue samples. These findings suggest that S100A14 negatively regulates 
expression and activity of MMP1 and MMP9 and that might be responsible for the S100A14 
mediated regulation of tumor cell invasion. In conclusion, findings of this work suggest that 
differential expression of several of the S100 gene family members is a common genetic 
alteration in OSCCs. S100A14, similar to other members of the S100 family, is involved in 
key cellular functions such as cell cycle regulation and tumor cell invasion indicating a tumor 
suppressor role for S100A14. Uncontrolled cell proliferation and invasion, characteristics of 
OSCCs, might therefore be related to altered expression of S100A14 frequently observed in 
these cancers. 
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1. Introduction 
1.1. Oral squamous cell carcinoma (OSCC) 
Head and neck cancers encompass malignancies that arise in the oral cavity, nasal cavity, para 
nasal sinuses, pharynx and larynx. Oral cancers represent 40% of all head and neck cancers 
and consist of the malignancies arising in the lip, tongue, floor of the mouth, gingiva, palate 
and buccal mucosa [1, 2]. The most frequent neoplasms arising from the oral epithelium are 
oral squamous cell carcinomas (OSCCs), representing more than 90% of all oral cancers. 
Combined with pharyngeal cancers, oral cancers rank as the sixth most common type of 
cancer world-wide, being the third most common in the developing countries (for example, 
South and Southeast Asian countries: Pakistan, India, Sri Lanka, Taiwan; African countries: 
Sudan, etc) [3]. This wide geographical variation in the incidence of OSCCs has been linked 
with the country specific risk factors, for example: betel quid and smokeless tobacco in South 
and Southeast Asian countries [4] and toombak in the Sudan [5, 6]. Several etiological factors 
namely use of tobacco (smoked and smokeless) and alcohol, infection with human papilloma 
virus (HPV) or herpes simplex virus (HSV), dietary deficiencies or imbalances (micronutrient 
deficiency), genetic predisposition, etc have been linked with the development of OSCCs. 
Based on the available global evidence, Warnakulasurya S. has categorized risk factors for 
OSCCs into established, strongly suggestive, possible and speculative factors (Table 1) [7]. 
Table 1: Suggested risk factors for OSCCs (adapted from Warnakulasurya S [7]) 
              
Established   Strongly   Possible  Speculative 
    Suggestive               
Smoking   Sunlight (lip)  Viruses   Mouthwashes 
Tobacco chewing  Radiation  Immune deficiency Periodontal diseases 
Snuff (Toombak) dipping    Dentition?  Mate drinking 
Alcohol misuse      Ethnicity? 
Betel quid use               
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1.2. Potentially malignant oral disorders 
Oral carcinogenesis is believed to evolve as a multi-step process where the majority of 
OSCCs are thought to be preceded by or associated with potentially malignant (dysplastic) 
oral epithelial lesions. Several terms ‘pre-cancer’, ‘precursor lesions’, ‘intra-epithelial 
neoplasia’ and ‘potentially malignant’ have been used broadly and interchangeably to 
describe the clinical presentation of oral lesions that may have the potential to transform into 
cancer. Recently, the term ‘potentially malignant disorders’ has been recommended when 
referring to these lesions [8]. Leukoplakia (white patches) and erythoplakia (red patches), the 
most common form of potentially malignant oral disorders, carry high risk of malignant 
transformation. Malignant transformation rates up to 36% and 50% have been reported 
respectively for leukoplakia and erythoplakia [reviewed in 9]. Malignant transformation rates 
of these lesions are often correlated with the severity of the histological (dysplastic) changes. 
In addition, several molecular alterations have been identified and correlated with the 
malignant potential of these lesions. Despite the progress in the field of molecular biology, no 
single or a set of molecular markers can reliably predict the malignant transformation rates of 
oral premalignant lesions [10]. 
1.3. Molecular biology of OSCC 
Genetic damage lies central to the carcinogenesis process. It is generally accepted that 
alterations (usually mutations) in three classes of genes namely, oncogenes, tumor-suppressor 
genes and stability genes are responsible for the development of human cancers [reviewed in 
11]. Oncogenes are the genes whose protein products are either produced in higher amounts 
or have higher activity, hence acting in a dominant manner (gain of function). Oncogenes can 
be activated by chromosomal translocations or insertional mutagenesis, gene amplifications or 
by activating point mutations/deletions. On the other hand, tumor suppressor genes are the 
genes whose protein products have loss of function due to mutations and are recessive in 
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nature. Missense mutations at residues that are essential for the activity of protein, deletions 
or insertional mutations or epigenetic silencing result in loss of function of tumor suppressor 
genes. The stability genes or caretakers are involved in the repair of genetic damage induced 
during normal cell division or due to exposure with carcinogenic environment. Stability genes 
are also inactivated in a manner similar to that of the tumor suppressor genes [11, 12]. 
Mutations in these classes of genes ultimately result in the development of an invasive cancer 
characterized by self-sufficiency in growth signals, insensitivity to anti-growth signals, 
evasion of apoptosis, invasion and metastasis to local and distant organs, limitless replicative 
potential and sustained angiogenesis [13].  
 The oral cavity is frequently exposed to high levels of carcinogenic substances in the 
form of tobacco (such as benzo-(a)-pyrene and nitrosamines), alcohol or infection with 
oncogenic viruses, such as HPV. Consequently, and similar to other cancers, OSCCs also 
develop as a result of genetic changes caused by these carcinogens. It is generally accepted 
that combinations of these genetic changes initially result in the development of potentially 
malignant (dysplastic) oral lesion which may progress to invasive carcinoma under sustained 
additional genetic alterations [14]. Based on the genetic alterations reported in potentially 
malignant (dysplastic) oral lesions and oral cancers, Califano and colleagues have proposed a 
genetic progression model for head and neck squamous cell carcinoma (HNSCC) 
[14][reviewed in 15] (Figure 1). According to the model, a loss of chromosomal region 9p 
(p16INK4a and p14ARF) has been described in 70-80% of oral dysplastic lesions, and together 
with the inactivation of the remaining alleles of p16INK4a and p14ARF by promoter 
hypermethylation, it represents one of the earliest and the most frequent events involved in 
OSCC progression [14, reviewed in 15 and 16]. Loss of heterozygosity (LOH) of TP53 has 
been reported as early as in the dysplastic stage of oral carcinogenesis [14].  
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Recently, we conducted multi-country studies using high throughput molecular techniques 
like microarray, comparative genomic hybridization (CGH) and proteomics to dissect the 
possible changes in global gene and protein expression profiles, chromosomal abnormalities 
and deregulated molecular networks occurring during the transition from normal oral 
epithelium to OSCC. Alterations in the chromosomal regions harboring several members of 
the S100 and Matrix metalloproteinase (MMP) gene families were found to be common in the 
HNSCC/OSCC samples examined [17] (Suhr et al; unpublished data). Accordingly, 
differential mRNA and protein expression levels of members of the S100 and MMP genes 
were found in the HNSCCs/OSCCs examined [18-20]. We have also reported prevalence of 
HPV, HSV, and Epstein-Barr virus (EBV) DNA in a large number of potentially malignant 
(dysplastic) oral lesions/cancers examined from different populations suggesting their role in 
OSCC carcinogenesis [21, 22]. A predominance of differential expression of several members 
of the S100 proteins in the samples examined attracted our attention in understanding their 
possible role in OSCC carcinogenesis. 
 
Figure 1. Proposed multi-step genetic progression model of oral carcinogenesis (modified 
from Califano J et al; 1996 [14] and Choi S et al; 2007 [15]). 
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1.4. S100 gene family members 
 
Moore identified for the first time an unfractionated mixture of the S100B and S100A1 from 
the bovine brain and called it ‘S100’ because the mixture was soluble in 100% saturated 
solution of the ammonium sulphate solution [23]. S100 proteins are small acidic proteins (10-
12 kDa) that constitute the largest subfamily of calcium binding proteins of the EF-hand type. 
Among the 25 members (with a sequence homology of 25-65%) described till now, 21 
members (A100A1-S100A18, trichohylin, filaggrin and repetin) are clustered at chromosome 
locus 1q21, while the remaining members are located at loci 4p16 (S100P), 5q14 (S100Z), 
21q22 (S100B) and Xp22 (S100G) [24, reviewed in 25, 26]. 
 
 
Figure 2. Schematic illustration of the typical structure of the S100 protein (L1 and L2: 
calcium binding loops, H: hinge region, N and C: N- and C-terminals) (modified from Donato 
R, 2001 [27]) 
 
Structural analyses have revealed that most of the S100 proteins exist in cells as anti-parallel 
homo/hetero dimers. The S100 protein monomer consists of two calcium (Ca2+) binding 
motifs of the EF-hand type separated by a flexible region, the hinge (Figure 2). Each Ca2+ 
binding motif consists of a Ca2+ binding loop flanked by two -helices. Helices I and II flank 
the Ca2+ binding loop in the N-terminal site whereas the Ca2+ binding loop in the C-terminal 
site is flanked by III and IV helices. IV helix in the C-terminal site is followed by a C-
terminal extension. The C-terminal extension and the hinge region have the most sequence 
variability among the S100 proteins. Upon Ca2+ binding, the S100 dimer undergoes 
conformational change due to the reorientation of helices III and IV and forms clefts like 
target protein binding sites [28, 29]. Interacting with their target molecules in a Ca2+ -
dependent as well as an independent manner, S100 proteins regulate a range of biological 
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activities such as cell growth, cell motility, signal transduction, transcription, apoptosis and 
cell survival (Table 2).  
Table 2. Suggested functions and disease associations of selected members of the S100 
protein family 
               
S100 protein Postulated functions     Disease association [Ref.] 
              
S100A1 Regulation of cell motility, muscle contraction,  Cardiomyopathies [30] 
Phosphorylation, neurite overgrowth, 
regulation of Ca2+  
S100A2 Tumor suppressor functions, interaction with p53 Cancer [30, 31] 
 
S100A3 Hair shaft formation, inverse association with  Hair damage, Cancer [30, 32] 
tumor differentiation and TNM stage  
 
S100A4 Regulation of cell invasion, angiogenesis,  Cancer [30, 33, 34] 
cell proliferation, apoptosis, 
interaction with p53 
 
S100A5 Ca2+, Zn2+ and Cu2+- binding protein,   Cancer? [30, 35] 
  association with tumor recurrence   
 
S100A6 Regulation of cell growth and apoptosis,  Cancer [30, 36, 37] 
regulation of cytoskeletal dynamics, 
interaction with p53  
 
S100A7 Regulation of keratinocyte proliferation   Psoriasis, Cancer [30] 
and maturation, inflammation  
 
S100A8/A9 Chemotactic activities, myeloid cell   Inflammatory disorders, 
differentiation and maturation, arachidonic   Cancer [30] 
acid metabolism    
 
S100A10 Regulation of membrane traffic: ion channels,  Depressive disorders, 
regulation of phospholipase A2    Inflammation [38, 39] 
 
S100A11 Regulation of kerationcyte proliferation, role in  Cancer,  
keratinocyte cornified envelope formation,  Inflammation [30, 40] 
regulation of cytoskeletal components 
 
S100A12 Interaction with RAGE-inflammatory response,  Inflammatory conditions, 
chemotactic functions     Autoimmune disease [30, 41] 
 
S100A13 Regulation of FGF-1 release, association with  Tumor angiogenesis, 
tumor cell invasion     Invasion [30, 42] 
 
S100A14 Association with tumor invasion, differentiation  Cancer? [43] 
 
S100B  Cell motility, cell proliferation, survival   Developmental brain   
and differentiation, regulation of Ca2+,   dysfunction, 
extracellular functions, such as: neurite   Alzheimer’s Disease, 
  extension, interaction with p53    Down’s syndrome, 
         Depression, Cancer [30, 44] 
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A number of molecules including enzymes, cytoskeletal components, and transcription factors 
have been identified as targets for the S100 proteins [25, 27, 30]. The following observations 
(i) occurrence of frequent structural and numerical aberrations in the chromosomal region 
1q21 [45] (where most of the S100 gene members are located [24]) in human cancers, (ii) 
altered mRNA and protein expression levels of several of the S100 members in different 
human malignancies [46] and (iii) involvement of the S100 proteins in several biological 
functions (cell growth, cell motility, signal transduction, transcription, apoptosis and cell 
survival) related to normal development and tumorigenesis [27, 47, 48]; suggest that these 
proteins are closely related to human malignancies. Accordingly, in previous work from our 
group chromosomal rearrangements have been identified in the 1q12 chromosome locus and 
differential expression of S100A1 and S100A2 members in HNSCCs/OSCCs from different 
populations has been reported [17-19] (Suhr et al; unpublished data). Further comprehensive 
expression profiling of 16 of the S100 gene members carried out in this study identified 
S100A14, a recently discovered S100 gene member, to be frequently down-regulated in 
OSCCs and in the OSCC derived cell-lines. 
1.4.1. S100A14 
S100A14 was first identified in 2002 by analyzing human lung cancer cell lines [26] and 
subsequently in 2003 as a membrane-associated protein in breast cancer cells [49] (hence it is 
also known as Breast Cancer Membrane Protein 84, BCMP84). The S100A14 gene has been 
mapped to human chromosome 1q21 and reported to contain 4 exons and 3 introns encoding 
for a small acidic EF-hand type Ca++ binding protein (104 amino acids) with a predicted  
molecular weight of 11.66 kDa [26]. S100A14 shares significant similarities as well as 
differences with other S100 members. S100A14 shares 68% similarity and 38% identity to 
S100A13 and with other S100 members like S100A4 (62% similarity; 30% identity), S100A2 
(60% similarity; 30% identity), S100A10 (58% similarity; 31% identity), and S100A9 (55% 
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similarity; 34% identity) [26]. However, in contrast to other S100 members which consist of 3 
exons and 2 introns (except S100A5, consisting of 4 exons with exon 3 and 4 being the coding 
ones; S100A4, containing an additional alternatively spliced untranslated exon; and S100A11, 
with the coding sequence beginning already in the first exon), S100A14 contains 4 exons and 
3 introns with exons 2-4 being the translated ones [26]. Similarly, the Ca2+ binding loop at the 
N-terminal of the S100A14 protein contains 13-amino-acids loop which is in contrast to the 
14-amino-acids loop characteristic of the S100 protein family [26]. Moreover, the Ca2+ 
binding loop at the C-terminal has been reported to carry mutations thus handicapping the 
Ca2+ binding ability of the S100A14 [26].  
 Sequences upstream of the transcription initiation site of the S100A14 have been 
shown to contain consensus recognition sequences for a number of transcriptional factors like 
c-Myc/Max, AREB6, USF and E2 box repressor deltaEF1 [26]. Recently, p53 has been 
identified as a transcriptional regulator of S100A14 [50]. In addition, the S100A14 protein has 
been predicted to contain a number of post-translational modification sites for example: N-
glycosylation, protein kinase phosphorylation, casein kinase II phosphorylation and N-
myristoylation [26, 51]. These observations indicate that S100A14 is under tight transcription 
and post-translational control and these controlling mechanisms might be important for the 
regulation of S100A14 expression and function. Moreover, differential expression of 
S100A14 found in different human normal and tumor tissues [26, 43, 52, 53] suggests that its 
regulation may be tissue and context specific and its expression might be de-regulated in 
pathological conditions including human cancers. Nevertheless, the biological functions and 
molecular targets of S100A14 are largely unknown. 
1.4.2. Expression profile and sub-cellular localization of S100A14 
A variable abundance in the expression of the S100A14 transcript has been shown in several 
types of normal human and cancer tissues and cell-lines. Normal human colon tissue was 
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shown to express the highest amount of S100A14 mRNA, whereas moderate expression levels 
were reported in normal human tissues such as thymus, kidney, liver, small intestine, lung, 
breast, ovary, prostate, rectum, stomach, thyroid and uterus. In contrast, low S100A14 mRNA 
expression has been reported in normal heart and no expression in normal human brain, 
skeletal muscle, spleen, placenta and peripheral blood leukocytes [26]. Ovary, breast, uterus, 
lung, prostate and thyroid tumors have been shown to over-express S100A14 mRNA [26]. On 
the other hand, down-regulated expression of S100A14 mRNA has been demonstrated in 
kidney, rectum, colon and stomach tumors, oesophageal carcinoma, colorectal carcinoma and 
OSCCs [26, 43, 52, 53]. Cytoplasmic and perinuclear localization of S100A14 protein has 
been shown in cells derived from lung tumors [26]. Conversely, strong and weak membranous 
staining has been reported in normal and colorectal carcinoma tissues respectively [43]. 
Further, membranous to cytoplasmic translocation of S100A14 protein from the highly 
differentiated to the poorly differentiated (invading islands of cells) areas has been described 
in squamous cell tonsil carcinoma and bladder papillary transitional cell carcinoma [49]. 
1.4.3. Biological functions of S100A14 
The biological functions of the S100A14 are largely unknown. Nevertheless, the following 
observations suggest that S100A14 might be important in multiple biological functions: (i) 
S100 family members are ‘highly conserved multifunctional’ proteins [47] and S100A14 is a 
member of this family, (ii) S100A14 is found to be differentially expressed in different tissue 
types and human cancers, (iii) S100A14 is transcriptionally regulated by the tumor suppressor 
protein p53 [50], (iv) S100A14 has been shown to be localized in the plasma membrane, 
cytoplasm and perinuclear area with sub-cellular translocation in some of the tumor types. In 
support of this suggestion, decreased immunoexpression of S100A14 has been correlated with 
poor differentiation and high metastatic potential of colorectal carcinomas [43].  
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1.5. Cell cycle regulation 
The sequence of stages through which a living cell passes between one cell division and the 
next is called the cell cycle. This consists of two main phases: Interphase and M-phase. The 
interphase further consists of G0, G1, S and G2-phases where as M-phase includes mitosis 
and cytokinesis. G0 is the quiescent phase where the living cell no longer divides [12]. 
Cyclins and cyclin dependent kinases (CDKs) are the key players of cell cycle regulation. 
Cyclins form complexes with CDKs and the resulting Cyclin/CDK complexes are necessary 
for the cell to pass through the specific phases of cell cycle. However, normal cells tightly 
regulate cell cycle progression by incorporating specific check points (G1, G2 and M-
checkpoints) which sense signaling cues and respond either by allowing cell cycle to progress 
or by halting it until the errors are fixed, or alternatively by inducing the onset of apoptosis. 
CDK inhibitors (CDKi) [CIP/KIP family: p21WAF1/CIP1 (p21), p27KIP1 (p27), p57KIP2 (p57) and 
INK family: p15INK4b (p15), p16INK4a (p16), p18INK4c (p18), p19INK4d (p19)] provide one of the 
most important mechanisms for inactivating CDKs and thereby blocking the cell cycle at 
specific checkpoints. Among these inhibitors, p21, p27 and p16 are considered to be important 
for regulation of the G1 check point [54-56] (Figure 3). 
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1.5.1. p53, p21 and p27 proteins 
The tumor suppressor protein p53  
Cells are regularly challenged by various cellular stress conditions such as radiation-, drug-, 
or carcinogen-induced DNA damage or oncogene activation (Ras, Myc) or other cellular 
stresses like hypoxia and nucleotide depletion. These conditions may nurture tumor initiation. 
p53, the guardian of the genome, responds to these insults by eliciting a number of key 
cellular processes (cell cycle arrest, apoptosis, DNA repair, inhibition of angiogenesis), 
thereby protecting the cells from malignant transformation [reviewed in 57 and 58] (Figure 3). 
One of the major effects of p53 activation by upstream pathways is the induction of cell cycle 
arrest. p53 directly stimulates expression of CDKN1A (p21) and brings about the G1-phase 
cell cycle arrest (Figure 3) [59]. p53 also induces G2-phase cell cycle arrest by activating 
transcription of Gadd45, 14-3-3 and along with CDKN1A [57].  
 Under normal conditions, the amount of p53 protein in cells is kept at a low level, 
primarily due to ubiquitin proteasome mediated degradation [57, 60]. Once the cells are 
challenged by stress conditions, p53 escapes the degradation pathway and undergoes 
stabilization and nuclear accumulation. Regulation of p53 stabilization is one of the most 
effective mechanisms of controlling p53 activity. Stabilization of the p53 is a complex 
process which largely depends on the p53 negative regulator, Mdm2 (an E3-ubiquitin ligase). 
In addition to Mdm2, stability of p53 appears to be regulated by activities of other E3 ligases 
(pirh2 and Cop-1), deubiquitinases (HAUSP), regulatory proteins (MdmX, ARF), ubiquitin 
analogues (SUMO1, Nedd8) and post-translational modifications of p53 [57, 60]. Recently, 
several members of the S100 protein family (such as S100A2, S100A6, S100B) have been 
shown to interact with the p53 and these interactions have been suggested to be important for 
p53 stabilization, its nuclear accumulation and activity [37, 61, 62]. 
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Tumor cells, however, acquire certain mechanisms to inactivate the activity and functions of 
the p53. In more than 50% of human cancers, p53 is directly inactivated by mutations of the 
TP53 gene [63]. In other cases, p53 is indirectly inactivated either by binding to viral proteins 
or by alterations in the genes whose protein products interact with p53 or convey information 
to or from p53 or by mislocalization of p53 to cytoplasm [reviewed in 57].  
p21 protein 
 
The CDKi p21 is encoded by the CDKN1A gene. One of the important functions of p21 is the 
control of cell proliferation by regulating cell cycle kinetics. It specifically blocks the kinase 
activity of CDK2 and prevents the Cyclin E/CDK2 complex from phoshorylating Rb protein 
and thus inhibiting dissociation of E2F from Rb and E2F dependent transcription of genes 
necessary for DNA replication [64, 65] (Figure 3). Moreover, by binding with PCNA, p21 
also inhibits DNA synthesis [66].  
 Although mutations of the CDKN1A gene are rare events [67, 68], altered expression 
of p21 is a frequent finding in human malignancies including OSCCs [69, reviewed in 70 and 
71]. Expression of p21 is regulated both at the transcriptional and post-transcriptional levels 
[reviewed in 71]. p53 is one of the main transcriptional activators of p21. In response to 
cellular stresses, p53 activates transcription of CDKN1A and subsequently brings about the 
G1-phase cell cycle arrest [59]. Apart from p53-dependent regulation, several p53-
independent pathways also regulate transcription of p21 [reviewed in 71]. p21 is also 
subjected to post-transcriptional modification by proteasome dependent degradation and 
phosphorylation with subsequent cytoplasmic mislocalization [reviewed in 71]. 
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Figure 3. Simplified presentation of up- and down-stream signaling pathways of p53 and its 
interconnection with G1-phase cell cycle control through p21. Negative and positive 
regulators of cell cycle are marked respectively with green and red letters and/or boxes 
(modified from Pecorino L, 2006 [12] and Lapenna S et al; 2009 [72]). 
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p27 protein 
 
p27, encoded by the CDKN1B gene, was initially identified as an inhibitor of the cyclin E-
CDK2 complex [73]. Similar to p21, p27 blocks the activity of the Cyclin E/CDK2 complex 
resulting in G1-phase cell cycle arrest [73, 74] in response to growth factor deprivation, 
contact inhibition and loss of adhesion to extracellular matrix (ECM) (Figure 3) [75]. 
 Similar to p21, somatic mutations of the CDKN1B gene are rare events in human 
malignancies [76]. However, down-regulated expression of p27 is commonly found in human 
malignancies and is often correlated with poor clinical outcomes [77-79]. Regulation of p27 
activity is complex and is determined by the intracellular expression of p27, its distribution 
among different cyclin-CDK complexes and its sub-cellular localization. Although p27 
expression is regulated both at the transcriptional [80, 81] and translational levels [82, 83], 
ubiquitin dependent proteolysis is thought to be the primary mechanism determining the 
cellular p27 protein level [84]. 
1.5.2. S100 proteins, cell cycle regulation and tumor growth 
Differential expression of several members of the S100 protein family is a frequent finding in 
human malignancies. Several of the S100 protein members (S100A2 [85], S100A4 [reviewed 
in 86], S100A6 [87], S100A7 [reviewed in 88], S100A8/A9 [89], S100A11 [90] [reviewed in 
40]) have been linked with tumor proliferation and growth. Uncontrolled tumor growth, one 
of the hallmarks of human cancer, is frequently associated with impaired cell cycle control 
[13]. Although several of the S100 protein family members have been linked with regulation 
of the cell cycle control, the precise molecular mechanisms involved are, however, not fully 
understood. S100A2 is found to be frequently down-regulated in cancers and is considered as 
a putative tumor suppressor protein [46]. Forced over-expression of S100A2 has been shown 
to inhibit cellular proliferation associated with G1- and S-phase cell cycle arrest in KB cells 
[85]. Similarly, S100A4 knock-down mediated suppression of pancreatic cancer cell growth 
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has been reported to be associated with G2-phase cell cycle arrest [91]. Roles of S100 
members on cell cycle control have further been supported by the fact that several of these 
protein members, namely S100A2 [85], S100A7 [92], S100A11 [90] and S100B [62] have 
been shown to modulate important molecules involved in cell cycle regulation, including 
CDKi, p21 and p27.  
 In addition, several of the S100 proteins, namely S100A2 [31], S100A4 [34], S100A6 
[37, 61] and S100B [62, 93] have been shown to interact with p53, one of the key regulators 
of the cell cycle, with different functional effects. S100A2 has been shown to interact with the 
C-terminus of p53, thereby enhancing p53 induced transcriptional activity for CDKN1A (p21) 
[31]. Similarly, S100A6 has been reported to interact and stimulate p53 activity [37]. 
Conversely, interaction of S100A4 with the C-terminus of p53 has been shown to inhibit p53 
dependent transcriptional activation of CDKN1A [34]. However, controversy exists regarding 
interpretation of the interactions between S100B and p53. S100B has been reported to co-
operate with cPKC in regulating nuclear translocation of the wild type p53 thereby inducing 
p53-dependent transcriptional activation of CDKN1A and subsequent G1-phase cell cycle 
arrest [62]. On the other hand, S100B has also been demonstrated to inhibit the level of p53 
and its transcriptional activity [93, 94]. In addition to S100 protein-mediated regulation of p53 
function, p53 has been reported to regulate transcription of S100A2 [95], S100A6 [96] and 
S100A9 genes [97]. Recently, S100A14 has been identified as one of the transcriptional targets 
of p53 and this transcriptional regulation has been suggested to play a tumor suppressive role 
in esophageal squamous cell carcinoma [50]. Experimental evidence is, however, currently 
lacking to support these suggestions.  
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1.6. Tumor invasion and regulatory molecules: Role of MMPs 
 
Tumor invasion and metastasis is one of the hallmarks of human cancer [13]. It is a complex 
process involving molecular alterations in cell adhesion molecules (CAMs) and ECM 
degrading proteases. CAMs consist of a variety of molecules like cadherins, integrins, 
selectins, immunoglobin superfamily and others like CD44. In addition to providing a 
mechanical link between cell to cell and cell to ECM, CAMs are actively involved in 
bidirectional (cell to ECM and ECM to cell) cell signaling [reviewed in 98 and 99]. E- and P-
cadherins are expressed by keratinocytes and they provide cell-cell interactions and are also 
involved in intracellular signaling. Integrins represent the largest family of CAMs and they 
provide cell-ECM interactions. They are found as a heterodimer of  (16 different types) and 
 (8 different types) subunits and the different combinations of heterodimer recognize 
different ECM components. Once bound to their ligands, integrins mediate bidirectional 
signaling important for regulation of cell motility, cell survival and cell proliferation [12, 
reviewed in 100].  
Proteolytic breakdown of cell-cell and cell-ECM interactions is necessary for invasion 
of tumor cells. Serine proteases and MMPs are the most important groups of proteases 
involved in tumor invasion and metastasis. MMPs are zinc-dependent endopeptidases 
consisting of more than 21 members which can cleave virtually any components of ECM 
[reviewed in 101]. By degrading ECM, MMPs not only allow cancer cells to invade into the 
stroma but also release other molecules (eg: growth factors) involved in cell growth, 
differentiation, apoptosis, angiogenesis and immune surveillance. Because of their 
involvement in multiple biological functions, the activity of MMPs is tightly regulated at 
various levels. In addition to transcriptional regulation, MMPs are synthesized as latent 
enzymes and need proteolytic cleavage for their activation. Moreover, endogenous tissue 
inhibitors (TIMPs) also regulate their activity [reviewed in 101]. However, cancer cells 
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acquire mechanisms to overcome such regulation and most of the metastatic cancers, 
including OSCCs, are often associated with increased expression and activity of several 
members of the MMPs [19, 20, 98, 102]. Accordingly, increased expression and activity of 
MMPs has been shown to be associated with increased metastatic potential and poor clinical 
outcomes in OSCCs [103, 104]. Previous work from our group identified amplification of 
chromosomal loci harbouring MMP1, MMP3, MMP7, MMP8, MMP10, MMP12, MMP13 and 
MMP20 genes and accordingly up-regulation of several of the MMP members in 
HNSCCs/OSCCs examined from different populations [17-20] (Suhr et al; unpublished data).  
1.6.1. Role of S100 proteins in tumor invasion and metastasis 
Several of the S100 protein members have been implicated in tumor invasion and metastases. 
Some of them have been found to correlate positively while some negatively with tumor 
invasion and metastases. Accordingly, several lines of experimental data have shown their 
involvement in key processes related to tumor invasion and metastasis (cytoskeletal 
organization and cellular motility) [27] and modulation of  important molecules involved in 
cell adhesion and ECM degradation [46, 105]). Several in vivo and in vitro studies have linked 
over-expression of S100A4 (metastasin) with high invasion/metastatic potential and poor 
clinical outcomes in different human cancers [reviewed in 33, 105]. Metastasis promoting 
functions of the S100A4 have been related to its ability to modulate organization of 
cytoskeletal components [33], regulate expression of cell adhesion molecules (E-cadherin) 
[106] and regulate expression and activity of MMPs (MMP9 [107], MMP13 [108]). 
Functional association of other S100 members like S100A2 [109, 110], S100A6 [111], 
S100A8/A9 [112], S100A13 [42] and S100P [113] has also been demonstrated with tumor 
invasion. Recently, decreased immunoexpression of S100A14 has been shown to be 
correlated with high metastatic potential of colorectal cancers [43]. Nevertheless, the 
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functional significance and the molecular mechanisms of S100A14 in tumor invasion and 
metastasis are largely unknown.  
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2. Aims of the study 
 
Previous work from our group, using high throughput genomic and proteomic methods, has 
identified differential expression of members of the S100 proteins in OSCCs/HNSCCs [18, 
19]. These findings triggered further expression studies on S100 gene members (Paper I) and 
investigation of the possible biological significance of one of the S100 members, in-particular 
S100A14, in OSCCs (Papers II and III).  
General aims: 
To identify differentially expressed S100 gene family members in OSCCs and further to 
explore the possible functional role(s) and the associated molecular pathways related to 
S100A14 in OSCC progression. 
Specific aims: 
I. To investigate the differentially expressed S100 gene family members (S100A1, S100A2, 
S100A3, S100A4, S100A6, S100A7, S100A8, S100A9, S100A10, S100A11, S100A12, 
S100A13, S100A14, S100B, S100P and S100Z) in OSCCs compared to their pair-wised 
normal controls and to correlate the findings with patients’ clinicopathological 
parameters (Paper I). 
II. To examine the expression pattern and sub-cellular localization of S100A14 in archival 
normal human oral mucosa (NHOM), oral dysplastic lesion (ODL) and OSCC tissue 
specimens and in an in vitro human OSCC progression model (Papers II and III).  
III. To explore the biological role of S100A14 in regulation of OSCC derived cell 
proliferation and its functional association with the tumor suppressor protein p53 (Paper 
II).  
IV. To investigate the functional role of S100A14 in regulation of OSCC cell invasion in 
vitro and to identify cell adhesion and invasion related molecules modulated by 
S100A14 (Paper III 
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3. Materials and methods 
The materials and laboratory methods used in the study have been described in detail in the 
original papers included in the thesis. Therefore, a summary is presented here (Figure 4).  
 
 
Figure 4. Flow chart illustrating the methodology used in the study 
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3.1. Patients, tissue specimens and cells 
Both human tissue specimens and cells (in vitro) derived from normal, dysplastic and 
cancerous human oral epithelial tissues have been used in this study. NHOM tissues used to 
generate the keratinocyte primary culture and all other tissue specimens used in this study 
were obtained after written consent. This study was approved by the Regional Committees for 
Medical Ethics in Research. 
3.1.1. Patients and tissue specimens 
Table 3. Summary of the tissue specimens and the laboratory methods used in the study 
              
Tissue specimens  Sample no.(n) Procedures used    Paper 
              
OSCCs/pair-wised  27  sRT-PCR1 & qRT-PCR2 for S100 genes  I 
normal controls (Sudan) 
 
OSCCs/pair-wised  8  sRT-PCR & qRT-PCR for S100 genes  I 
normal controls (Norway) 
 
NHOM, ODL and OSCCs 13, 10 and 16 IHC3 for S100A14    III 
(Sudan & Norway) 
 
OSCCs/pair-wised  19  qRT-PCR for MMP1, MMP9 & S100A14 III 
normal controls (Sudan) 
              
1semiquantitative RT-PCR; 2quantitative RT-PCR; 3immunohistochemistry 
 
 
3.1.2. Cell culture (in vitro OSCC progression model) 
An in vitro OSCC progression model consisting of cells derived from NHOM (NOK 94, 
NOK95, NOK108; n=3), ODL (POE9n [114] , D20 [115], DOK [116]; n=3) and oral 
carcinoma (SCC4 [117], SCC25 [117], H357 [118], VB6 [119], UK1 [120], CA1 [120], 5PT 
(T. Carey, University of Michigan), CaLH3 [121]; n=8) and OSCC tissues was used in the 
study (Papers II and III).  
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3.1.3. Selection of CaLH3 cell-line as an in vitro working model 
Our main in vitro working model in papers II and III included the CaLH3 cell-line [121] 
derived from a primary OSCC located in the ventral surface of the tongue. We selected this 
cell-line for our work because of the following reasons: 
I. It has satisfactory growth and handling characteristics. 
II. It expresses an appreciable amount of S100A14 protein and this allows us to modulate 
(over-express or knock-down) the endogenous S100A14 expression according to the 
need of the experiment. 
III. It harbors wild type (wt) p53 protein (exons 5 to 9 were sequenced) and this provides us 
with an opportunity to examine the possible involvement of p53 protein in S100A14 
mediated functional effects. 
3.2. mRNA and protein analyses  
Several laboratory methods were used to profile expression of mRNA and protein levels and 
to investigate protein localization. mRNA levels were examined by sRT-PCR (Paper I) and 
qRT-PCR (Papers I-III). SYBR green based pathway focussed PCR Array (SABiosciences) 
was used to profile CAMs and ECM molecules (Paper III). Protein expression levels were 
examined by western blot (WB) analysis (Papers II and III). Proteolytic activity of MMP9 
was examined by gelatine zymography (Paper III). Protein localization was examined by 
immunohistochemistry (IHC) (Paper III) and double indirect immunofluorescence (DIF) 
(Paper II). TaqMan assays used for qRT-PCR are summarized in Table 4. Details of the 
primary and secondary antibodies used for western blot, IHC and double indirect 
immunofluorescence are summarized in Table 5. 
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Table 4. Details of the TaqMan assays used in the study 
            
Gene   Ref Seq  TaqMan assay ID amplicon length (bp) 
            
S100A1  NM_006271  Hs00196704_m1  74 
S100A4  NM_002961  Hs00243201_m1  57 
S100A6  NM_014624  Hs00170953_m1  94 
S100A7  NM_002963  Hs00161488_m1  105 
S100A8  NM_002964  Hs00374263_m1  70 
S100A14 NM_020672  Hs00221080_m1  92 
TP53  NM_001126112 Hs00153349_m1  72 
Bcl-2  NM_000633  Hs00236808_s1  130 
Bax  NM_138761  Hs00180269_m1  62 
CDKN2A NM_058195  Hs00923894_m1  115 
CDKN1A NM_078467  Hs00355782_m1  66 
CDKN1B NM_004064.3  Hs00153277_m1  71 
MMP1  NM_002421  Hs00233958_m1  133 
MMP9  NM_004994.2  Hs00957562_m1  67 
FN1  NM_212474  Hs01549976_m1  81 
CD44  NM_001001389 Hs00153304_m1  86 
            
 
Table 5. Reagents and conditions used for WB, IHC and DIF. 
              
Appl. Target  Species  Catalog / Soruce  Dilution  Buffer*  
              
WB S100A14 P (rabbit) 10489-1-AP / Proteintech 1/1000  5% BSA / 1hr 
WB p21  M  556430 / BD pharmingen 1/200  5% BSA / 1hr 
WB p27  M  p2092/ DCS-72 / Sigma 1/200  5% BSA / 1hr 
WB p53  M  sc-263 / Santa Cruz  1/1000  5% BSA / 1hr 
WB p16  P (rabbit) sc-468 / Santa Cruz  1/200  5% BSA / 1hr 
WB Bax  M  sc-20067 / Santa Cruz  1/1000  5% BSA / 1hr 
WB Bcl-2  P (rabbit) sc-783 / Santa Cruz  1/500  5% BSA / 1hr 
WB GAPDH M  ab 9484 / Abcam  1/5000  5% BSA / 1hr 
WB Lamin A/C P (rabbit) #2032 / Cell Signalling  1/1000  5% milk /ON§ 
WB Anti-mouse P (donkey) 715-035-150 / Jackson  1/1000  5% milk / 1hr 
     Immuno Research 
WB Anti-rabbit P (donkey) 711-035-152 / Jackson  1/1000  5% milk / 1hr 
     Immuno Research 
              
IHC S100A14 P (rabbit) 10489-1-AP / Proteintech 1/500  AD / 1hr 
IHC Anti-rabbit P (Goat) DAKO  - -   30 min 
              
DIF S100A14 P (rabbit) 10489-1-AP / Proteintech 1/1000  AD / 1hr 
DIF p53  M  DO-7 / DAKO   1/10  AD / 1hr, RT 
DIF Anti-mouse P (goat) Alexa Fluor 594 /   1/500  AD / 1hr, RT 
     Invitrogen 
DIF Anti-rabbit P (goat) Alexa Fluor 488 /  1/500  AD / 1hr, RT 
     Invitrogen 
              
* TBST (Tris Buffered Saline, pH 7.4 with 0.1% Tween-20); § 4 °C, all other incubations at room 
temperature; Appl Applications; M monoclonal; P polyclonal; AD antibody diluent, DAKO; ON 
overnight 
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3.3. Selection of the endogenous control 
RT-PCR is a highly sensitive laboratory technique. Hence, selection of an appropriate 
endogenous control is extremely important to normalize RT-PCR expression data. We tested 
3 endogenous controls (GAPDH, 18S and ACTB) and GAPDH (with the lowest variation 
across the samples) was used to normalize both sRT-PCR and qRT-PCR data in paper I. 
Further, we tested 5 endogenous controls (B2M, HPRT1, RPL13A, GAPDH and ACTB) 
included in the PCR array across cell-lines derived from NHOM (NOK94, NOK95 and 
NOK108), ODL (D20 and DOK) and OSCCs (SCC4, SCC25). Their expression data were 
analyzed with NormFinder software (version 0.953) [122] and GAPDH with the lowest 
stability value (0.218) (the stability value is directly proportional to the variation in the 
expression status of the endogenous control gene across the samples) was used to normalize 
the data for all experiments (Figure 5). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Five endogenous controls were examined using NormFinder software. GAPDH, 
followed by ACTB, were found to be the best working endogenous controls for gene 
expression profiling studies.  
3.4. Modulation of S100A14 expression in vitro 
The functional significance of S100A14 was examined by using retroviral vector mediated 
over-expression and siRNA mediated knock-down of the endogenous S100A14. Following 
successful over-expression and knock-down of the S100A14, in vitro assays were carried out. 
CaLH3 and H357 cells infected with retrovirus with S100A14 insert and retrovirus without 
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S100A14 insert are referred to as ‘S100A14-CaLH3 and S100A14-H357’ and ‘control-
CaLH3 and control-H357’, respectively. Similarly, CaLH3 cells treated with scrambled and 
S100A14 siRNA are referred to as ‘sc-siRNA’ and ‘S100A14-siRNA’ cells, respectively. 
S100A14 shares significant similarity with other members of the S100 family. Thus 
specificity of S100A14 retroviral expression vector and S100A14 siRNA was verified by 
examining mRNA expression of other S100 gene members related to S100A14, namely 
S100A13, S100A4, S100A10 and S100A9. mRNA expression levels of these S100A14 related 
genes were found to be unaltered both in control and treated CaLH3 and H357 cell-lines, 
suggesting high specificity of the S100A14 retroviral expression vector and S100A14 siRNA 
used. 
3.5. Functional assays 
Effects of S100A14 over-expression/knock-down on cell proliferation (WST-1 assay), 
apoptosis (Annexin-V assay), cell cycle kinetics (Propidium Iodide staining and flow 
cytometry) and cell invasion (Matrigel invasion assay) were examined using established in 
vitro methods.  
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4. Summary of the results and discussion 
I. Differential expression of the members of the S100 gene family in OSCCs: down-
regulation of S100A14 in OSCC specimens and OSCC derived cell-line in vitro (Papers I-
III) 
Both genotypic and phenotypic alterations characterize malignant transformation of normal 
cells. Among the different genetic alterations found in human cancers, increasing numbers of 
the S100 gene family members have been described in connection with tumorigenesis because 
of their differential expression found in human malignancies and their association with 
several key biological functions. In this study, a comprehensive expression profiling of 16 of 
the S100 gene family members (S100A1, S100A2, S100A3, S100A4, S100A6, S100A7, S100A8, 
S100A9, S100A10, S100A11, S100A12, S100A13, S100A14, S100B, S100P and S100Z) using 
sRT-PCR and further verification with qRT-PCR revealed altered mRNA expression of 
several of the S100 gene members examined in OSCCs. Four of the S100 members (S100A4, 
S100A6, S100A8 and S10014) were found to be significantly down-regulated (p<0.05) in the 
OSCCs (n=27) examined from the Sudan compared to their pair-wised normal controls 
(Figure 6A). S100A14 was also found to be down-regulated in the OSCC cases examined 
from Norway (n=8) (p=0.015) (Figure 6B). Similar to these findings, altered expression of 
S100 gene family members has been reported in several human cancers [reviewed in 46, 52, 
123] suggesting their association with human carcinogenesis. Though the exact mechanism 
for differential expression of S100 gene members in human cancers is largely unknown, yet 
several possible explanations have been proposed. Firstly, frequent structural and numerical 
aberrations in the chromosomal region 1q21 [45, 124] (where most of the S100 members are 
located [24]) have been reported in a variety of human cancers. 
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Figure 6. Means of the mRNA expression levels of 16 S100 gene members examined in 
OSCCs from Sudan (A). Mean of the S100A14 mRNA expression in OSCCs from Norway 
(B). Error bars in figures (A) and (B) represent standard error of the mean (SEM). 
Distribution of S100A14 mRNA in OSCCs and their pair-wised normal controls from Sudan 
(C) and Norway (D). (E) Means of S100A14 mRNA expression levels in the in vitro OSCC 
progression model. Error bars represent standard deviation (SD). 
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Supporting these observations, previous studies from our group have shown chromosomal 
rearrangements in the 1q21 region harbouring most of the S100 gene members in 
HNSCCs/OSCCs examined from different populations [17] (Suhr et al; unpublished 
observations). These findings indicate that chromosomal rearrangements might be one of the 
mechanisms for the differential expression of the S100 gene members in the OSCC cases 
examined. Secondly, it has been shown that the chromosome region 1q21-1q22 contains 
extended regions of high CpG island density [125]. The methylation status of CpG islands in 
the promoter region has been shown to regulate the transcription of genes. Interestingly, 
differential expression of many S100 gene members in different cancer types has been shown 
to be associated with the methylation status of CpG islands in S100 genes [126-130]. 
Therefore, it is possible that the down-regulated expression of S100 gene members found in 
OSCCs might also be due to transcription repression by hypermethylation of CpG islands. 
This suggestion, however, requires further investigation. 
 Mirroring down-regulated expression of the S100A14 mRNA in Sudanese and 
Norwegian OSCC cases (Figure 6C and D), S100A14 immunoexpression was found to be 
weaker in the OSCCs; especially in the invading islands of tumor cells (Figure 7; Figure 1 in 
Paper III). These findings were paralleled by the in vitro data where S100A14 mRNA 
(Figure 6E) and protein (Figure 1 in Paper II) levels were found to be down-regulated in the 
OSCC derived cell-lines compared to that of the normal oral keratinocytes. These 
observations indicate that loss of S100A14 is closely associated with OSCC progression. In 
addition, S100A14 mRNA and protein levels were found to be altered in the dysplastic cell-
lines compared to the normal oral keratinocytes in vitro (Figure 6E; Figure 1 in Paper II), 
suggesting that de-regulation of S100A14 might be an early event in OSCC carcinogenesis. 
Immunohistochemical analysis of S100A14 in ODL (n=10), although showed a 
heterogeneous expression pattern with some ODL displaying weaker and some showing 
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stronger S100A14 staining compared to that of the NHOM, supports the notion that altered 
expression of S100A14 might be an early molecular event in OSCC carcinogenesis. 
Nevertheless, further investigation using a large cohort of specimens is warranted to confirm 
these findings and to examine the possibility of ‘translational relevance’ of the expression 
pattern of S100A14 in ODL.  
 
 
Figure 7. Expression and sub-cellular localization of the S100A14 in NHOM and OSCC as 
examined by IHC. Representative NHOM (A) specimen showing strong membranous 
S100A14 expression in the epithelial compartment. (B) OSCC lesion showing a gradient of 
S100A14 immunostaining- remains of the superficial epithelium (arrows) shows a strong, 
membranous staining in contrast to a weak, predominantly cytoplasmic staining in the tumor 
invading islands (arrowheads).(C) High magnification of the OSCC lesion demonstrating 
weak, predominantly cytoplasmic S100A14 staining in the tumor invading islands 
(arrowheads).  
 
 Down-regulation of S100A14 mRNA and protein levels found in the OSCCs and 
OSCC derived cell-lines is in agreement with previous reports in different human cancers [43, 
52]. Strong membranous S100A14 staining in NHOM compared to weak membranous and 
cytoplasmic staining in the invading tumor islands found in OSCC is in accordance with a 
previous report in colorectal carcinomas [43]. However, in their study the authors did not 
describe any change in sub-cellular localization in cancers compared to normal colorectal 
tissues in their study. A change in sub-cellular localization of S100A14 from membranous in 
the highly differentiated areas to cytoplasmic in the poorly differentiated areas has been 
described in tonsil squamous cell carcinoma and bladder papillary transitional cell carcinoma 
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[49]. This is in agreement with our observations that the invading islands of cells (poorly 
differentiated) showed mixed membranous and cytoplasmic or cytoplasmic staining compared 
to the membranous staining found in more differentiated (central/superficial) areas in OSCC 
and NHOM tissue specimens (Figure 1 in Paper III). These data suggest that membranous 
S100A14 might play a role in establishing cell-cell contacts in non-invading cells and that this 
function might be lost in the invading cancer cells perhaps due to membrane to cytoplasmic 
switch of S100A14 sub-cellular localization. However, this suggestion needs to be rigorously 
tested. In contrary, an opposite S100A14 staining pattern and sub-cellular localization has 
been claimed in breast cancers [49]. Nevertheless, only 17% (10 out of 58) of the breast 
cancers examined have been described to express strong S100A14 immunoreactivity in their 
study and this implies that 83% of the cases were perhaps weaker in S100A14 expression [49]. 
Nonetheless, the differences in the expression and sub-cellular localization of S100A14 might 
be due to differences in the source of the archival tissues used (oral vs. breast), indicating the 
possibility of a context dependent regulation of S100A14 expression, or due to the procedural 
differences in IHC (among others, we have used Tris-EDTA, pH9 and while the authors have 
used Citrate buffer, pH6 supplemented with 1mg/mL pepsin treatment for antigen retrieval).  
 Down-regulation of the S100A14 was found at the transcriptional level in the tissue 
samples of OSCC and in the OSCC derived cell-lines. This could be due to rearrangement of 
the S100A14 locus as evidenced by a high degree of chromosomal rearrangement of the 1q21 
region found in HNSCCs/OSCCs [17] (Suhr et al; unpublished observations). Conversely, no 
deletions or gross rearrangement have been reported for the S100A14 gene in lung cancer cell-
lines [26]. This discrepancy could be due to different genetic alterations found in different 
tissues of origin (oral vs. lung) and therefore this finding cannot completely rule out the 
correlation of down-regulated expression of S100A14 in OSCCs with the frequently observed 
rearrangements in 1q21 region found in HNSCC and other human cancers. On the other hand, 
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hypermethylation of CpG islands is a very unlikely mechanism for this down-regulation since 
no CpG islands have been reported in the S100A14 gene [26]. In addition, sequences upstream 
of the transcription initiation site of S100A14 have been suggested to contain consensus 
recognition sequences for a number of transcriptional factors like c-Myc/Max, AREB6, USF 
and E2 box repressor deltaEF1; and negative regulatory elements like TCF11-, NF-kB-, c-
Ets1-, MZF1-, and estrogen receptor-binding sites [26]. These observations further suggest 
the possible existence of other regulatory mechanisms for S100A14 expression and indicate 
S100A14 to be a major player in a complex molecular interplay involved in biological 
processes. 
 Altered expression of many S100 members has been described in connection with 
different aspects of tumorigenesis, like cell proliferation and apoptosis [85, 87, 89-91, 131, 
132], tumor invasion and metastasis [reviewed in 105, 106, 110, 111]. In addition, different 
sub-cellular localization of S100A6 and S100A11 proteins have been described to be 
associated with cell proliferation, tumor progression and poor clinical outcomes [90, 133-135]. 
Hence, both quantitative (expression) and qualitative (sub-cellular localization) changes of 
S100A14 expression might be associated with change/alteration in the function of this protein 
and that might be important in the OSCC tumorigenesis process. 
II. S100A14 over-expression mediated regulation of cell cycle and cell proliferation (Paper 
II) 
One of the hallmarks of cancer is uncontrolled tumor growth [13]. The key determinants of 
tumor growth are rate of cell proliferation (cell division) and cell death (apoptosis). It is 
obvious that abnormalities in the mechanisms controlling cell proliferation and/or apoptosis 
might lead to excessive cellular growth. Cancer cells frequently acquire genetic defects 
(abilities) to escape these mechanisms and proliferate in an uncontrolled fashion. We found 
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down-regulation of S100A14 both in OSCC specimens and in OSCC derived cell-lines, 
indicating that loss of S100A14 might be related to the OSCC progression.  
 Examination of the cellular proliferation showed that CaLH3 cells proliferated 
significantly slower when S100A14 was over-expressed by employing retroviral expression 
vector. In addition, higher fraction of S100A14-CaLH3 cells was found to be arrested in the 
G1-phase of cell cycle (Figure 3 in Paper II). Taken together, these data indicate that 
S100A14 over-expression inhibits proliferation of S100A14-CaLH3 cells by inducing G1-
phase cell cycle arrest. Further, over-expression and siRNA mediated knock-down of 
S100A14 was found to be associated with up-and down-regulation of the CDKi p21 and p27 
in CaLH3 cells (Figure 3 in Paper II). These findings imply that p21 and p27 proteins 
function downstream of the S100A14 protein and this functional association is related to the 
observed G1-phase cell cycle arrest in S100A14-CaLH3 cells. It is therefore possible that loss 
of S100A14 expression in OSCCs might enable tumor cells to escape S100A14 mediated 
control over the cell cycle, thus allowing them to proliferate excessively. 
III. S100A14 over-expression mediated regulation of p53 activity and function (Paper II) 
The observations that (i) several members of the S100 protein family interact with p53 both 
with stimulating as well as inhibiting effects on p53 functions relevant for human 
carcinogenesis [31, 34, 37, 61, 93, 94] (ii) S100A14 over-expression induced G1-phase cell 
cycle arrest with up-regulation of p21 (one of the key transcriptional targets of p53) in CaLH3 
cell-line; led us to investigate the possible involvement of p53 in the S100A14 mediated 
functional effect on the cell cycle. shRNA mediated knock-down of p53 resulted in 
suppression of p21 expression in S100A14-CaLH3 cells, indicating that S100A14 over-
expression mediated p21 up-regulation was indeed dependent on the activity of p53 (Figure 3 
in Paper II). Supporting these findings, inhibition of cell proliferation, induction of G1-phase 
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cell cycle arrest or up-regulation of p21 protein was not found by over-expressing S100A14 in 
the H357 cell-line harboring a mutated and non-functional p53 (Figure 5 in Paper II).  
Examination of the TP53 mRNA, total and nuclear-cytoplasmic p53 protein analyses showed 
that S100A14 over-expression was associated with nuclear accumulation of p53, without any 
effect on the transcription of TP53; indicating that S100A14 over-expression enhances 
stability and subsequent nuclear accumulation of p53 (Figure 4 in Paper II). Since nuclear 
accumulation of p53 is considered as one of the major mechanisms to enhance p53 activity 
[60, 136], we propose that S100A14 over-expression promotes p53 activity by favoring p53 
nuclear accumulation and that might be related with the p21 up-regulation and the G1-cell 
cycle arrest in CaLH3 cells. In fact, modulation of p53 activity by favoring p53 nuclear 
accumulation has been suggested for other members of the S100 proteins, such as S100A6 [37] 
and S100B [62].  
 Chen et al have recently shown that S100A14 gene is a transcriptional target of p53 
[50]. Given the fact that S100A14 regulates nuclear accumulation and activity of p53 as 
shown in the current study, it is possible that there exists a mutual positive functional 
regulation between p53 and S100A14 and that might be important in the tumor suppressive 
functions involved in OSCC carcinogenesis. Such mutual regulation between S100A2 and 
p53 has already been suggested [31, 95]. 
IV. S100A14 over-expression mediated regulation of tumor cell invasion through 
modulation of MMP1 and MMP9 expression and activity (Paper III) 
OSCC is a highly aggressive pathological condition characterized by frequent metastatic 
involvement of the cervical lymph nodes, resulting in a severely reduced patient survival [137, 
138]. A cascade of qualitative and quantitative molecular (intracellular, intercellular and cell-
ECM) alterations influences the invasive potential of cancer cells and also modulates the 
ECM microenvironment to support the motility of cancer cells. Our findings of (i) 
 49
weak/absent S100A14 immunoexpression in the invading islands of tumor cells compared to 
the more superficial areas in OSCCs (ii) membrane to cytoplasmic switch of the S100A14 
sub-cellular localization in the invading islands of tumor cells in OSCCs (iii) weak/absent 
S100A14 mRNA expression in invasive VB6, H357 and SCC25 oral carcinoma derived cell-
lines; suggest that S100A14 expression might be associated with the invasive phenotype of 
OSCC. This idea has further been substantiated by previous reports where reduced expression 
of S100A14 has been correlated with the increased metastatic potential in colorectal 
carcinomas [43]. Moreover, a change in sub-cellular localization of the S100A14 from 
membranous in more differentiated (central) areas to cytoplasmic in poorly differentiated 
(invading) areas in tonsil squamous cell carcinoma and bladder papillary transitional cell 
carcinoma has also been reported [49].  
 Corroborating the observed correlation between loss of S100A14 expression and 
invasive phenotype of the cells in OSCC specimens and in the OSCC derived cell-lines, a 
functional role of S100A14 in tumor cell invasion was evidenced by the fact that over-
expression of endogenous S100A14 inhibited the invasive potential of CaLH3 (P=0.039) and 
H357 (P=0.066) cell-lines when using quantitative in vitro Matrigel invasion assay (Figure 4 
in Paper III). Supporting these findings, siRNA mediated knock-down of the S100A14 
promoted invasion of CaLH3 cells (P=0.011) (Figure 4 in Paper III). Collectively, these 
findings indicate that expression of S100A14 is negatively related with the invasive 
phenotype of tumor cells and loss of S100A14 expression in tumor cells might therefore 
contribute to the more invasive phenotype of these cells.  
 Unsupervised hierarchical cluster analysis of the PCR array data showed a distinct 
mRNA signature of the genes involved in tumor invasion and metastasis in control-CaLH3 
cells compared to the S100A14-CaLH3 cells. These observations indicate that S100A4 over-
expression mediated change in the invasive phenotype of S100A14-CaLH3 cells was indeed 
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related to the modulation of these invasion and metastasis related genes. In accordance, SAM 
analysis identified a number of invasion and metastasis promoting (MMP1, MMP9, FN1, 
CD44 and TNC) and suppressing genes (TIMP2) to be significantly (FDR=0) down- and up-
regulated, respectively, in S100A14-CaLH3 cells. S100A14-CaLH3 cells expressed 12.63 and 
8.38 folds less MMP1 and MMP9 mRNAs compared to that of control-CaLH3 cells. In 
parallel, MMP1 and MMP9 mRNA levels were also found to be suppressed in S100A14-
H357 cells compared to the control-H357 cells (Figure 5 in Paper III). Additionally, activity 
of MMP9 was found to be suppressed in S100A14-CaLH3 cells (Figure 5 in Paper III). 
Overall, these data suggest that MMP9 and MMP1 are among the key targets of S100A14 and 
suppression of their expression and activity might contribute to the S100A14 over-expression 
mediated reduction of the invasive potential of tumor cells. These suggestions were also 
reflected in the OSCCs specimens where MMP1 and MMP9 mRNA expression levels were 
found to be inversely correlated with the S100A14 mRNA level. Given the fact that MMP9 
and MMP1 are frequently over-expressed and are associated with increased metastatic 
potential and poor clinical outcomes in OSCCs [139-142], it is possible that one way the 
transformed cells can acquire an invasive phenotype might be through the up-regulation of 
MMP9 and MMP1 by down-regulating S100A14 expression. 
 In conclusion, these data propose that S100A14 regulates the invasive phenotype of 
OSCC derived cells by modulating expression and activity of MMP1 and MMP9. Down-
regulation of S100A14 found in OSCCs might be associated with the increased invasive and 
metastasis potential of the tumor cells and that might explain a high rate of cervical lymph 
node metastasis found in these lesions. 
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5. Conclusions 
 
A comprehensive mRNA expression profiling of 16 of the S100 gene members in OSCCs was 
carried out and functional roles and related molecular networks were characterized for the 
S100A14. The following conclusions can be drawn based on the data of the current study: 
I. Differential expression of S100 gene members is a common molecular change found in 
the OSCCs examined, indicating a close association of these gene members with oral 
carcinogenesis.  
II. Down-regulation of S100A14 is a common molecular alteration observed in OSCCs, 
highlighting its role in progression of OSCC. 
III. S100A14 mediated inhibition of OSCC cell proliferation due to G1- arrest through 
nuclear accumulation of p53 and p53-dependent up-regulation of p21 indicates that the 
functional relation between S100A14 and p53 plays a tumor suppressive role in OSCC 
carcinogenesis. 
IV. S100A14 over-expression mediated inhibition of OSCC cell invasion with concomitant 
suppression of MMP1 and MMP9 expression and activity suggest that down-regulation 
of S100A14 found in OSCCs might be related to increased invasive and metastasis 
potential of these lesions. 
V. Down-regulated expression of S100A14 in OSCCs and its involvement in the inhibition 
of cell proliferation and invasion of OSCC derived cells suggests that S100A14 might 
function as a tumor suppressive protein in OSCC carcinogenesis (Figure 8). 
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Figure 8. Involvement of S100A14 in cell proliferation and cell invasion, suggesting a tumor 
suppressive role for S100A14. Question mark 1 (?1) indicates unknown mechanism 
associated with nuclear accumulation of p53. ?2,?3 and ?4 illustrate unknown  mechanisms 
involved in the regulation of the indicated molecules. 
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6. Future perspectives 
 
Further investigations are necessary to confirm and to extend the findings of the current study 
employing additional in vitro and in vivo model systems.  
I. Regulation of the expression of S100A14 in OSCCs 
Down-regulation of S100A14 was found in OSCCs and in OSCC derived cell-lines. 
Although some of the possible mechanisms for this down-regulation have been 
discussed, further investigations will be necessary to fully understand the molecular 
mechanisms involved in S100A14 expression.  
II. Signalling between S100A14, p53 and p27 
This study provided evidence that S100A14 over-expression mediated up-regulation of 
p21 is p53-dependent. However, the molecular mechanisms related to nuclear 
accumulation of p53 and up-regulation of p27 associated with S100A14 over-expression 
need to be examined. 
III. S100A14 mediated modulation of identified invasion and metastasis related genes, 
in particular MMP1 and MMP9 
Some of the molecular mechanisms (nucleobindin mediated G protein-coupled signal 
transduction, Paper III) possibly involved in the modulation of mRNA expression of 
MMP1 and MMP9 and other invasion and metastasis related genes associated with 
S100A14 over-expression have been discussed in the current work. However, this 
possibility needs to be rigorously established.  
IV. Significance of membrane to cytoplasmic switch of S100A14 in invading islands of 
tumor cells 
The functional and clinical significance and molecular mechanisms associated with 
membrane to cytoplasmic switch of S100A14 protein in OSCCs need to be elucidated.  
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V. Translational relevance 
Altered expression of S100A14 was noticed even in the dysplastic stage. In addition, 
findings such as loss of S100A14 in invasive islands of tumor cells with membrane to 
cytoplasmic switch strongly indicate association of the S100A14 expression pattern with 
the progression of disease and its severity. These associations/correlations, though not 
rigorously established in this study definitely warrant further investigation, and 
represent promising variables that might be useful in clinical settings. 
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